Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus - PubMed
Multicenter Study
doi: 10.1093/cid/cis500. Epub 2012 May 18.
Elena Rodríguez, Pilar Miralles, Miguel A Von Wichmann, José López-Aldeguer, Josep Mallolas, María J Galindo, Eva Van Den Eynde, María J Téllez, Carmen Quereda, Antoni Jou, José Sanz, Carlos Barros, Ignacio Santos, Federico Pulido, Josep M Guardiola, Enrique Ortega, Rafael Rubio, Juan J Jusdado, María L Montes, Gabriel Gaspar, Herminia Esteban, José M Bellón, Juan González-García; GESIDA HIV/HCV Cohort Study Group
Affiliations
- PMID: 22610932
- DOI: 10.1093/cid/cis500
Multicenter Study
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus
Juan Berenguer et al. Clin Infect Dis. 2012 Sep.
Abstract
Background: Sustained virological response (SVR) after therapy with interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). We assessed the effect of SVR on HIV progression and mortality not related to liver disease.
Methods: An observational cohort study including consecutive HIV/HCV-coinfected patients treated with interferon plus ribavirin between 2000 and 2008 in 19 centers in Spain.
Results: Of 1599 patients, 626 (39%) had an SVR. After a median follow-up of approximately 5 years, we confirmed that failure to achieve an SVR was associated with an increased risk of liver-related events and liver-related death. We also observed higher rates of the following events in nonresponders than in responders: AIDS-defining conditions (rate per 100 person years, 0.84 [95% confidence interval (CI), .59-1.10] vs 0.29 [.10-.48]; P= .003), non-liver-related deaths (0.65 [.42-.87] vs 0.16 [.02-.30]; P = .002), and non-liver-related, non-AIDS-related deaths (0.55 [.34-.75] vs 0.16 [.02-.30]; P = .002). Cox regression analysis showed that the adjusted hazard ratios of new AIDS-defining conditions, non-liver-related deaths, and non-liver-related, non-AIDS-related deaths for nonresponders compared with responders were 1.90 (95% CI, .89-4.10; P = .095), 3.19 (1.21-8.40; P = .019), and 2.85 (1.07-7.60; P = .036), respectively.
Conclusions: Our findings suggest that eradication of HCV after therapy with interferon plus ribavirin in HIV/HCV-coinfected patients is associated not only with a reduction in liver-related events but also with a reduction in HIV progression and mortality not related to liver disease.
Similar articles
-
Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group. Berenguer J, et al. Hepatology. 2009 Aug;50(2):407-13. doi: 10.1002/hep.23020. Hepatology. 2009. PMID: 19575364
-
Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Clin Infect Dis. 2013 Jun;56(11):1646-53. doi: 10.1093/cid/cit103. Epub 2013 Feb 19. Clin Infect Dis. 2013. PMID: 23429381
-
Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC. Peribañez-Gonzalez M, et al. Ann Hepatol. 2013 Mar-Apr;12(2):228-35. Ann Hepatol. 2013. PMID: 23396734
-
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Simmons B, et al. Clin Infect Dis. 2016 Mar 15;62(6):683-694. doi: 10.1093/cid/civ948. Epub 2016 Jan 19. Clin Infect Dis. 2016. PMID: 26787172 Free PMC article. Review.
-
Basso M, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicolè S, Cruciani M, Palù G. Basso M, et al. HIV Clin Trials. 2013 Jul-Aug;14(4):127-39. doi: 10.1310/hct1404-127. HIV Clin Trials. 2013. PMID: 23924585 Review.
Cited by
-
Brochado Ó, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S; GESIDA Study Group. Brochado Ó, et al. J Biomed Sci. 2021 Mar 30;28(1):23. doi: 10.1186/s12929-021-00718-6. J Biomed Sci. 2021. PMID: 33785040 Free PMC article.
-
Casado JL, Esteban MA, Bañón S, Moreno A, Perez-Elías MJ, Mateos ML, Moreno S, Quereda C. Casado JL, et al. Dig Dis Sci. 2015 Nov;60(11):3473-81. doi: 10.1007/s10620-015-3773-y. Epub 2015 Jun 26. Dig Dis Sci. 2015. PMID: 26112991
-
Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. Kidney Int Suppl (2011). 2018 Oct;8(3):91-165. doi: 10.1016/j.kisu.2018.06.001. Epub 2018 Sep 19. Kidney Int Suppl (2011). 2018. PMID: 30675443 Free PMC article. No abstract available.
-
Skinner NE, Vergara C, El-Diwany R, Paul H, Skaist A, Wheelan SJ, Thomas DL, Ray SC, Balagopal A, Bailey JR. Skinner NE, et al. Viral Immunol. 2021 Nov;34(9):622-631. doi: 10.1089/vim.2021.0027. Epub 2021 Oct 21. Viral Immunol. 2021. PMID: 34672777 Free PMC article.
-
Hepatitis C virus infection: looking for interferon free regimens.
González-Moreno J, Payeras-Cifre A. González-Moreno J, et al. ScientificWorldJournal. 2013 Apr 9;2013:825375. doi: 10.1155/2013/825375. Print 2013. ScientificWorldJournal. 2013. PMID: 23710151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical